Page last updated: 2024-12-08

nla 1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NLA 1: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID368824
CHEMBL ID541282
SCHEMBL ID8909002
MeSH IDM0196794

Synonyms (17)

Synonym
140448-36-8
nsc 640116
9-acridinamine, n-(3-(2-nitro-1h-imidazol-1-yl)propyl)-, monohydrochloride
n-(3-(2-nitro-1h-imidazol-1-yl)propyl)-9-acridinamine monohydrochloride
nla 1
nla-1
nsc-640116
CHEMBL541282
SCHEMBL8909002
9-[3-(2-nitro-1-imidazolyl) propylamino]acridine hydrochloride
n-[3-(2-nitroimidazol-1-yl)propyl]acridin-9-amine;hydrochloride
DTXSID70930840
n-[3-(2-nitro-1h-imidazol-1-yl)propyl]acridin-9(10h)-imine--hydrogen chloride (1/1)
55KV4C37DS
n-[3-(2-nitro-1h-imidazol-1-yl)propyl]-9-acridinamine hydrochloride (1:1)
9-acridinamine, n-[3-(2-nitro-1h-imidazol-1-yl)propyl]-, hydrochloride (1:1)
AKOS040753292
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID21048Partition coefficient in octanol/water2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID228276Concentration required to reduce fluorescence in ethidium bromide displacement assay using EB-DNA complex2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216742Cytotoxicity of compound was measured against suspended V79 cells under aerobic conditions in clonogenic assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216743Cytotoxicity of compound was measured against suspended V79 cells under hypoxic conditions in clonogenic assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216883In vitro therapeutic index of compound was measured inV79 cells2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID231440Ratio (HS) of CT50 values in aerobic condition to hypoxic condition (in N2 presence) given as CT50(A)/CT50(H)2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.04 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]